Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-R

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer is a phase 2, interventional study registered as NCT06369259 by M.D. Anderson Cancer Center, with a registry enrolment figure of 33 participants, started 2025-02-24 and due to reach its primary completion in 2029-02-01. Interventions recorded: Defactinib; Cetuximab; Avutometinib. Conditions listed: Advanced Colorectal Cancer. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* Histologically (or cytologically) confirmed diagnosis of adenocarcinoma of the colon or rectum, with clinical confirmation of unresectable and/or metastatic disease that is measurable according to RECIST1". Sites: United States. No results are recorded here; the registry entry is the source.